Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture

Noriaki Kawano, Hidenobu Ochiai, Shuro Yoshida, Kiyoshi Yamashita, Kotaro Shide, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Keiko Katayose, Takanori Toyama, Hiroshi Kawano, Hitoshi Matsuoka, Junzo Ishizaki, Koichi Maeda, Seiichi Satou, Tatsuhiko Yano, Kenichiro Yamaguchi, Katsuto Takenaka, Yoshiya Shimao, Koichi Oshima & 2 others Akira Ueda, Kazuya Shimoda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.

Original languageEnglish
Pages (from-to)336-340
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Lymphoma
Central Nervous System
Lymphoma, Large B-Cell, Diffuse
Recurrence
Mantle-Cell Lymphoma
T-Cell Lymphoma
Cerebrum
B-Cell Lymphoma
Therapeutics
Rare Diseases
Basal Ganglia
Methotrexate
Cerebellum
B-Lymphocytes
Radiotherapy
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. / Kawano, Noriaki; Ochiai, Hidenobu; Yoshida, Shuro; Yamashita, Kiyoshi; Shide, Kotaro; Shimoda, Haruko; Hidaka, Tomonori; Kubuki, Yoko; Katayose, Keiko; Toyama, Takanori; Kawano, Hiroshi; Matsuoka, Hitoshi; Ishizaki, Junzo; Maeda, Koichi; Satou, Seiichi; Yano, Tatsuhiko; Yamaguchi, Kenichiro; Takenaka, Katsuto; Shimao, Yoshiya; Oshima, Koichi; Ueda, Akira; Shimoda, Kazuya.

In: International Journal of Clinical Oncology, Vol. 17, No. 4, 01.08.2012, p. 336-340.

Research output: Contribution to journalArticle

Kawano, N, Ochiai, H, Yoshida, S, Yamashita, K, Shide, K, Shimoda, H, Hidaka, T, Kubuki, Y, Katayose, K, Toyama, T, Kawano, H, Matsuoka, H, Ishizaki, J, Maeda, K, Satou, S, Yano, T, Yamaguchi, K, Takenaka, K, Shimao, Y, Oshima, K, Ueda, A & Shimoda, K 2012, 'Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture', International Journal of Clinical Oncology, vol. 17, no. 4, pp. 336-340. https://doi.org/10.1007/s10147-011-0292-5
Kawano, Noriaki ; Ochiai, Hidenobu ; Yoshida, Shuro ; Yamashita, Kiyoshi ; Shide, Kotaro ; Shimoda, Haruko ; Hidaka, Tomonori ; Kubuki, Yoko ; Katayose, Keiko ; Toyama, Takanori ; Kawano, Hiroshi ; Matsuoka, Hitoshi ; Ishizaki, Junzo ; Maeda, Koichi ; Satou, Seiichi ; Yano, Tatsuhiko ; Yamaguchi, Kenichiro ; Takenaka, Katsuto ; Shimao, Yoshiya ; Oshima, Koichi ; Ueda, Akira ; Shimoda, Kazuya. / Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. In: International Journal of Clinical Oncology. 2012 ; Vol. 17, No. 4. pp. 336-340.
@article{bc0133dbff064698a8e8afdedf90bf38,
title = "Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture",
abstract = "Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67{\%}); the other 3 patients (33{\%}) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.",
author = "Noriaki Kawano and Hidenobu Ochiai and Shuro Yoshida and Kiyoshi Yamashita and Kotaro Shide and Haruko Shimoda and Tomonori Hidaka and Yoko Kubuki and Keiko Katayose and Takanori Toyama and Hiroshi Kawano and Hitoshi Matsuoka and Junzo Ishizaki and Koichi Maeda and Seiichi Satou and Tatsuhiko Yano and Kenichiro Yamaguchi and Katsuto Takenaka and Yoshiya Shimao and Koichi Oshima and Akira Ueda and Kazuya Shimoda",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s10147-011-0292-5",
language = "English",
volume = "17",
pages = "336--340",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture

AU - Kawano, Noriaki

AU - Ochiai, Hidenobu

AU - Yoshida, Shuro

AU - Yamashita, Kiyoshi

AU - Shide, Kotaro

AU - Shimoda, Haruko

AU - Hidaka, Tomonori

AU - Kubuki, Yoko

AU - Katayose, Keiko

AU - Toyama, Takanori

AU - Kawano, Hiroshi

AU - Matsuoka, Hitoshi

AU - Ishizaki, Junzo

AU - Maeda, Koichi

AU - Satou, Seiichi

AU - Yano, Tatsuhiko

AU - Yamaguchi, Kenichiro

AU - Takenaka, Katsuto

AU - Shimao, Yoshiya

AU - Oshima, Koichi

AU - Ueda, Akira

AU - Shimoda, Kazuya

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.

AB - Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.

UR - http://www.scopus.com/inward/record.url?scp=84867329304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867329304&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0292-5

DO - 10.1007/s10147-011-0292-5

M3 - Article

VL - 17

SP - 336

EP - 340

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -